Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

209 results about "Ursodeoxycholic acid" patented technology

Ursodiol is used to dissolve certain types of gallstones, to prevent gallstones from forming in obese patients who are losing weight rapidly, and to treat a certain type of liver disease (primary biliary cirrhosis).

Reducing ER stress in the treatment of obesity and diabetes

InactiveUS20060073213A1Reduce ER stressIncrease insulin sensitivitySalicyclic acid active ingredientsBiocidePeripheral insulin resistanceTauroursodeoxycholic acid
Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Preparation of hyaluronic-acid-based double-targeting nano-composite medicament and application of double-targeting nano-composite medicament

The invention relates to a hyaluronic-acid-based double-targeting nano-composite medicament and a preparation method thereof. Hydrophobic group ursodeoxycholic acid is included in a hyaluronic acid nano-polymer structure and can form an amphipathic polymer and automatically generate micelles in an aqueous solution, and polyethylene glycol can be introduced into the micelles to improve the dispersity and stability of a composite. An anti-tumor medicament can enter a nano-carrier through electrostatic adsorption or physical inclusion to generate a nano-medicament composite, wherein the nano-medicament composite is selectively concentrated in a tumor cell under an active targeting effect of hyaluronic acid and a surface CD44 receptor of a tumor cell, and promotes a tumor tissue to absorb the nano medicament-carrying composite by using a passive osmotic accumulation effect (EPR) at the same time. After an anti-tumor medicament is wrapped by a modified hyaluronic acid polymer, the anti-tumor medicament has the advantages of improving the bioavailability of the medicament, improving the targeting property, reducing the toxic and side effects, prolonging the half-life period of the medicament, being stably stored and the like, so that the tumor targeting therapy efficiency is improved in many ways.
Owner:XIAMEN UNIV

Preparation method of ursodeoxycholic acid

The invention provides a preparation method of ursodeoxycholic acid. Commercial available chenodeoxycholic acid is taken as raw materials, the ursodeoxycholic acid is obtained by four steps including selective oxidation, esterification, deoxidation and hydrolyzation, and the total yield is 85.7%. In a mixture of acetone and water, NBS is used for selective oxidation of hydroxy at C- 7 bit of the chenodeoxycholic acid, and the selective oxidation possesses excellent selectivity and high yield. NaBH14 / CeC13 may be used to deoxidize carbonyl at C-7 bit into hydroxy, and the ratio of alpha / beta is as high as 5 / 95.
Owner:EAST CHINA UNIV OF SCI & TECH

Method of preparing tauroursodeoxycholic acid by biotransformation and application of method

The invention discloses a method of preparing tauroursodeoxycholic acid by biotransformation and application of the method. Biotransformation includes genetic codon optimization, engineered bacteria construction, engineered bacteria cultivation, substrate transformation and product preparation. Tauroursodeoxycholic acid is prepared by transforming a substrate through direct fermentation of engineered bacteria; the substrate is taurochenodeoxycholic acid. The substrate may reach 250 g / L in concentration; the reaction time is short; substrate transformation rate reaches 98% and above; the obtained product reaches 99% and above in purity; cyclic regeneration of NAD+ (nicotinamide adenine dinucleotide +) in the reaction system helps greatly reduce the usage of the coenzyme NAD+; the cost of enzymic catalytic reaction is reduced; industrial amplification is benefited. hydroxysteroid dehydrogenase and the regenerated coenzyme are connected via a flexible polypeptide sequence to form a protein fusion polymer; binding distances to the substrate and coenzyme are shorter; transformation progress is more facilitated; the number of fermenting times in industrial production is decreased; the process is simplified; time cost and material cost are saved.
Owner:JIANGSU BANGZE BIOLOGICAL MEDICINE TECH CO LTD

Compound feed for enhancing physiological functions of intestinal mucosa and liver/pancreas cells of fishes

The invention belongs to a feed, and particularly relates to a compound feed for enhancing the physiological functions of intestinal mucosa and liver / pancreas cells of fishes, which contains fish meal, soybean meal, rapeseed meal, cottonseed meal, wheat, rice bran, rice bran meal, calcium biphosphate, zeolite powder, bentonite, DL carnitine, soybean oil, vitamin-mineral premix, ursodeoxycholic acid, taurine, glutamine and yeast culture. An experimental fish raised with feed, which serves as an experimental fish for the separation and primary culture of intestinal mucosa cells and liver cells,can obtain healthy intestinal mucosa cells and healthy liver cells, moreover, the physiological condition of the experimental fish can be kept in consistency, and the repeatability of a separation and primary culture experiment on the intestinal mucosa cells and the liver cells.
Owner:SUZHOU UNIV

7beta-hydroxysterol dehydrogenase mutant and application of 7beta-hydroxysterol dehydrogenase mutant in ursodeoxycholic acid synthesis

The invention discloses a 7beta-hydroxysterol dehydrogenase mutant with increased activity and stability which is obtained through molecular evolution, recombinant expression plasmid containing the 7beta-hydroxysterol dehydrogenase mutant gene and a recombinant expression transformant and a preparation method of a recombinant mutant enzyme preparation, and the invention also provides an application of the recombinant mutant enzyme preparation in ursodeoxycholic acid synthesis. The 7beta-hydroxysterol dehydrogenase has excellent activity and heat stability, can efficiently catalyze asymmetric reduction of 7-carbonyl lithocholic acid to prepare the ursodeoxycholic acid; the 7beta-hydroxysterol dehydrogenase is subjected to immobilization and then is subjected to couple by an enzyme method with the immobilized 7beta-hydroxysterol dehydrogenase, epimerization of a substrate chenodeoxycholic acid with low cost can be directly catalyzed, ursodeoxycholic acid can be prepared through continuous conversion, and the operation is simple. Compared with the prior art reported currently, ursodeoxycholic acid prepared by hydroxysterol dehydrogenase through catalysis has the advantages of high substrate concentration, short reaction time, complete reaction, and high product purity, and has strong industrial application prospect.
Owner:EAST CHINA UNIV OF SCI & TECH +1

Novel 7alpha-hydroxysteroid dehydrogenase knockout mutants and use thereof

The invention relates to novel microbial 7alpha-hydroxysteroid dehydrogenase (7alpha-HSDH) knockout mutants and to the use thereof for producing other HSDHs having various functionalities, such as 3alpha-, 7beta- or 12alpha-HSDH, and to the use of thus-produced HSDH enzymes in enzymatic reactions of cholic acid compounds, and in particular for producing ursodeoxycholic acid (UDCS). The invention relates in particular to novel methods for synthesizing UDCS.
Owner:CELL PHARM CO LTD

Method for synthesizing ursodeoxycholic acid through enzymatic method

The invention discloses a method for synthesizing ursodeoxycholic acid through an enzymatic method and a method for synthesizing the ursodeoxycholic acid by taking chenodeoxycholic acid as a raw material. The method takes the chenodeoxycholic acid as a base material and comprises the following steps: dissolving the chenodeoxycholic acid into a 50mM phosphate buffer solution; firstly, catalyticallyoxidizing the chenodeoxycholic acid by utilizing 7-alpha hydroxysteroid dehydrogenase in the presence of NAD, NOX2 and under the condition that oxygen is introduced, so as to obtain 7-ketolithocholicacid; then under the condition that the NAD, L-malic acid and malic dehydrogenase exist, catalytically reducing the 7-ketolithocholic acid by utilizing the 7-alpha hydroxysteroid dehydrogenase to obtain the ursodeoxycholic acid. According to the method disclosed by the invention, an organic solvent is not used and operation is simple; reaction conditions are moderate and easy to control and the utilization rate of the raw materials is high; the conversion rate reaches 99 percent or more.
Owner:ZHONGSHAN BAILING BIOTECHNOLOGY CO LTD

Ursodeoxycholic acid nano suspension and preparation method thereof

The invention discloses an ursodeoxycholic acid nano suspension and a preparation method thereof, relates to the field of pharmaceutical nano formulation, and particularly relates to an ursodeoxycholic acid nano suspension for curing cholestatic cirrhosis and dry powder thereof. The ursodeoxycholic acid nano suspension is characterized by adopting SDS and PVP K30 as surfactants and combining the SDS and the PVP K30 in a weight ratio of 1:1-1:3; and the ursodeoxycholic acid nano suspension has stable quality, with particle size of about 200-800nm. The invention also discloses a preparation method of the suspension.
Owner:302 MILITARY HOSPITAL OF CHINA

Method for synthesizing ursodeoxycholic acid and high-chiral-purity D-amino acid based on enzyme-method coupling technology

The invention discloses a method for synthesizing ursodeoxycholic acid (UDCA) and high-chiral-purity D-amino acid based on an enzyme-method coupling technology. The method comprises the following steps: putting chenodeoxycholic acid and alpha-ketonic acid into a solution system containing 7alpha-HSDH (Homoserine Dehydrogenase), DAADH and NADP (Nicotinamide Adenine Dinucleotide Phosphate) and carrying out enzyme catalysis reaction; separating a reaction solution by adopting an ultra-filtration membrane to obtain a concentrated mixed enzyme solution; regulating the pH (Potential of Hydrogen) ofa dialysis solution and crystallizing; filtering and separating to obtain 7-KLCA wet powder and filtrate; carrying out chromatographic treatment on the filtrate to obtain the D-amino acid; putting the7-KLCA wet powder into a solution system containing glucose, the NADP, the 7alpha-HSDH and GDH (Glutamate Dehydrogenase) and carrying out enzyme catalysis reaction; separating the reaction solution by adopting the ultra-filtration membrane to obtain the concentrated mixed enzyme solution; crystallizing, filtering and separating the dialysis solution, so as to obtain ursodeoxycholic acid. By adopting the method provided by the invention, UDCA and the high-chiral-purity D-amino acid can be obtained at the same time, the enzyme utilization rate is high, synthesis steps are simple and the cost isreduced; meanwhile, a metal reduction reagent and an organic solvent do not need to be added in a reaction process and conditions are mild; the method is environmentally friendly and is suitable forindustrial production.
Owner:HUNAN BAOLISHI BIOTECH

Composition and preparation for resisting ageing and improving male energy, preparation method of preparation and application of composition

The invention discloses a composition for resisting ageing and improving male energy. The composition is prepared from a raw material and an auxiliary material; the raw material is prepared from the following components in parts by weight: 1-15 parts of nicotinamide mononucleotide, 1-10 parts of protopanoxadiol, 1-9 parts of icarisid I, 2-8 parts of baohuoside I, 3-7 parts of dehydroepiandrosterone and 2-10 parts of ursodesoxycholic acid. The composition is reasonable in composing prescription and proper in compatibility; in the composition, the four of the nicotinamide mononucleotide (NMN), the icarisid I, the baohuoside I and protopanoxadiol are used as monarch drugs together, the composition is capable of comprehensively regulating gonad axis and invigorating kidney-yang and liver, candelay ageing period of the gonad axis and improve the sexual function after being taken for a long time; through intercoordination and synergistic effect of various components, the composition is comprehensive in nutrition, has very good palatability, is particularly suitable for males to take and thus relieving the symptoms of male ageing syndrome and improving the male energy. The invention alsoprovides a preparation containing the composition and a preparation method of the preparation. The preparation method is simple, is moderate in condition and is suitable for industrial batch production.
Owner:HOBOOMLIFE BIO TECH SHENZHEN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products